FindMyKOL
Clinical trialNCT06807580RecruitingPhase 2Interventional

Progesterone in Gender Affirming Hormone Therapy Study

NCT06807580 is a phase 2 interventional trial sponsored by Emory University. As of 21 Nov 2026, it is recruiting participants. It studies Placebo and Progesterone in Transgender Women. The registry lists an enrollment of 40 participants at 1 site in 1 country. The registry lists a start date of 12 May 2025 and a primary completion date of 28 Feb 2027.

SponsorEmory University →Enrollment40Transgender Women
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT06807580
FieldValue
Registry IDNCT06807580
StatusRecruiting
PhasePhase 2
Study typeInterventional trial
Lead sponsorEmory University
Enrollment40
Registered sites1
Countries1
ConditionsTransgender Women
DrugsPlacebo and Progesterone
Start12 May 2025
Primary completion28 Feb 2027
Study completion28 Feb 2027
Last update posted24 Dec 2025

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study aims to study the effects of Oral Progesterone in Transgender Women. The primary goal is to study the effect of progesterone on psychological distress and secondarily on sleep quality, breast size, quality of life and gender congruence and cardiovascular risk.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Georgia, United States1 site, 1 recruiting
  • Emory Transgender Clinic

    Atlanta

    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgia: 1 site, 1 recruitingGA1HawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT06807580

Each answer restates registry values shown on this page.

What is NCT06807580?

NCT06807580 is a phase 2 interventional trial sponsored by Emory University. It studies Placebo and Progesterone in Transgender Women.

Is NCT06807580 recruiting?

As of 21 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.

Who leads NCT06807580?

The registry names Vin Tangpricha, MD, PhD (principal investigator, Emory University) as the overall official.

Where does NCT06807580 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT06807580 study?

The registered drug and biological interventions are Placebo and Progesterone.

When is NCT06807580 expected to complete?

The registry lists a primary completion date of 28 Feb 2027 and a study completion date of 28 Feb 2027. The sponsor last updated the record on 24 Dec 2025.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.